Current Environment: Production

Medical Services

Specialties

Programs & Services

Education

Medical School

Columbia College of Physicians & Surgeons

1993, New York, NY

Residency

Pediatrics

Babies and Children's Hospital, College of Physicians & Surgeons, Columbia University Medical Center

1997, New York, NY

Fellowship

Pediatric Hematology/Oncology

Memorial Sloan Kettering Cancer Center

2003, New York, NY

Certifications

  • American Board of Pediatrics (General)
  • American Board of Pediatrics (Hematology-Oncology)

Professional History

Dr. Susan Prockop is an attending on the pediatric stem cell transplant program. Dr. Prockop trained in Pediatric Hematology Oncology at Memorial Sloan Kettering Cancer Center/Weill Cornell where she joined the faculty in 2004 specializing in the care of children and young adults with life-threatening blood disorders including cancer, myelodysplastic syndromes (MDS), and non-malignant disorders of blood forming and immune cells. Dr Prockop has specific expertise in the care of patients with immune deficiencies and immune dysregulation and is passionate about the importance of working with a multidisciplinary team to address the needs of each patient and their family. She conducts research that aims to improve the outcomes of children undergoing stem cell transplant and to move advances in the field of transplant, gene and cellular therapies to patients in need as rapidly as possible.

Dr. Prockop moved to Dana Farber/Boston Children’s in 2021 as the Program Director for Clinical and Translational Research and the Outpatient Clinic. In Boston she is continuing her work investigating the role of viral specific T cells in the treatment of EBV and CMV infections in patients with defects in their intrinsic immune control of these viruses. In addition, Dr. Prockop works with teams from centers across the United States and Internationally as a collaborative member of committees who share her goals. She is a principal investigator and co-investigator of several multicenter transplant, cellular therapy, and gene therapy clinical trials and is designing treatment regimens with the aim of reducing the side effects of stem cell transplantation by limiting the risk of the post-transplant complications of graft versus host disease and infection and using less toxic chemotherapy.

Publications

  1. Delayed T cell recovery after hematopoietic cell transplantation is associated with decreased overall survival in adults. Blood Adv. 2025 Apr 18. View Abstract

  2. Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies. Blood Adv. 2025 Apr 08; 9(7):1644-1657. View Abstract

  3. The Golgi complex governs natural killer cell lytic granule positioning to promote directionality in cytotoxicity. Cell Rep. 2025 01 28; 44(1):115156. View Abstract

  4. Multiomics dissection of human RAG deficiency reveals distinctive patterns of immune dysregulation but a common inflammatory signature. Sci Immunol. 2025 Jan 10; 10(103):eadq1697. View Abstract

  5. Allogeneic haematopoietic stem-cell transplantation for children with refractory systemic juvenile idiopathic arthritis and associated lung disease: outcomes from an international, retrospective cohort study. Lancet Rheumatol. 2025 Apr; 7(4):e243-e251. View Abstract

  6. Successful hematopoietic cell transplantation utilizing myeloablative reduced-toxicity conditioning in Chediak-Higashi syndrome. J Allergy Clin Immunol. 2025 Feb; 155(2):659-661. View Abstract

  7. Releasing our model T - chimeric antigen receptor (CAR) T-cells for autoimmune indications. Curr Opin Rheumatol. 2025 Mar 01; 37(2):128-135. View Abstract

  8. Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunity. Blood Adv. 2024 10 08; 8(19):5137-5145. View Abstract

  9. The role of the conditioning regimen for autologous and ex vivo genetically modified hematopoietic stem cell-based therapies: recommendations from the ISCT stem cell engineering committee. Cytotherapy. 2025 Jan; 27(1):78-84. View Abstract

  10. Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol. Blood Adv. 2024 06 25; 8(12):3001-3012. View Abstract

  11. Immune milestones to predict CMV after letermovir. Blood Adv. 2024 06 11; 8(11):2964-2966. View Abstract

  12. International Society for Cell & Gene Therapy Stem Cell Engineering Committee report on the current state of hematopoietic stem and progenitor cell-based genomic therapies and the challenges faced. Cytotherapy. 2024 Nov; 26(11):1411-1420. View Abstract

  13. Editorial: Checkpoint inhibition in hematologic malignancies. Front Oncol. 2024; 14:1429854. View Abstract

  14. A Novel Combination of Compound Heterozygous Variants in IFNGR1 Causing Complete IFNGR1 Deficiency. J Clin Immunol. 2024 04 27; 44(5):111. View Abstract

  15. Persistent or New Cytopenias Predict Relapse Better than Routine Bone Marrow Aspirate Evaluations After Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome in Children and Young Adult Patients. Transplant Cell Ther. 2024 Jul; 30(7):692.e1-692.e12. View Abstract

  16. Strategic infection prevention after genetically modified hematopoietic stem cell therapies: recommendations from the International Society for Cell & Gene Therapy Stem Cell Engineering Committee. Cytotherapy. 2024 Jul; 26(7):660-671. View Abstract

  17. Relevance of lymphocyte proliferation to PHA in severe combined immunodeficiency (SCID) and T cell lymphopenia. Clin Immunol. 2024 04; 261:109942. View Abstract

  18. Impact of rabbit anti-thymocyte globulin (ATG) exposure on outcomes after ex vivo T-cell-depleted hematopoietic cell transplantation in pediatric and young adult patients. Cytotherapy. 2024 04; 26(4):351-359. View Abstract

  19. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial. Lancet Oncol. 2024 Mar; 25(3):376-387. View Abstract

  20. Allogeneic hematopoietic cell transplantation is effective for p47phox chronic granulomatous disease: A  Primary Immune Deficiency Treatment Consortium study. J Allergy Clin Immunol. 2024 May; 153(5):1423-1431.e2. View Abstract

  21. Virus-specific T-cells from third party or transplant donors for treatment of EBV lymphoproliferative diseases arising post hematopoietic cell or solid organ transplantation. Front Immunol. 2023; 14:1290059. View Abstract

  22. Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & Europe. Pediatr Rheumatol Online J. 2024 Jan 05; 21(Suppl 1):86. View Abstract

  23. Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD. Blood. 2023 12 14; 142(24):2105-2118. View Abstract

  24. Engineering the best transplant outcome for high-risk acute myeloid leukemia: the donor, the graft and beyond. Cytotherapy. 2024 06; 26(6):546-555. View Abstract

  25. Treatment of recurrent pediatric myelodysplastic syndrome post hematopoietic stem cell transplantation. Clin Case Rep. 2023 Nov; 11(11):e8190. View Abstract

  26. Opportunistic Infections in Patients Receiving Post-Transplantation Cyclophosphamide: Impact of Haploidentical versus Unrelated Donor Allograft. Transplant Cell Ther. 2024 Feb; 30(2):233.e1-233.e14. View Abstract

  27. Posttransplantation late complications increase over time for patients with SCID: A Primary Immune Deficiency Treatment Consortium (PIDTC) landmark study. J Allergy Clin Immunol. 2024 01; 153(1):287-296. View Abstract

  28. T-cell depleted allogeneic hematopoietic stem cell transplant for the treatment of Fanconi anemia and MDS/AML. Bone Marrow Transplant. 2024 01; 59(1):23-33. View Abstract

  29. Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantation. Blood Adv. 2023 09 26; 7(18):5225-5233. View Abstract

  30. Development of a Screening Algorithm for Lung Disease in Systemic Juvenile Idiopathic Arthritis. ACR Open Rheumatol. 2023 Oct; 5(10):556-562. View Abstract

  31. Excellent leukemia control after second hematopoietic cell transplants with unrelated cord blood grafts for post-transplant relapse in pediatric patients. Front Oncol. 2023; 13:1221782. View Abstract

  32. Case Report: Cytomegalovirus-specific T-lymphocyte infusion for resistant cytomegalovirus retinitis. Front Ophthalmol (Lausanne). 2023; 3:1131674. View Abstract

  33. Emapalumab as bridge to hematopoietic cell transplant for STAT1 gain-of-function mutations. J Allergy Clin Immunol. 2023 09; 152(3):815-817. View Abstract

  34. Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium. Lancet. 2023 07 08; 402(10396):129-140. View Abstract

  35. Early immune reconstitution as predictor for outcomes after allogeneic hematopoietic cell transplant; a tri-institutional analysis. Cytotherapy. 2023 09; 25(9):977-985. View Abstract

  36. The current landscape: Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia. Best Pract Res Clin Haematol. 2023 09; 36(3):101485. View Abstract

  37. Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant. J Clin Invest. 2023 05 15; 133(10). View Abstract

  38. International Society for Cell & Gene Therapy Stem Cell Engineering Committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplant. Cytotherapy. 2023 06; 25(6):578-589. View Abstract

  39. Annexin A2 Loss After Cardiopulmonary Bypass and Development of Acute Postoperative Respiratory Dysfunction in Children. Crit Care Explor. 2023 Feb; 5(2):e0862. View Abstract

  40. Transplant for non-malignant disorders: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee report on the role of alternative donors, stem cell sources and graft engineering. Cytotherapy. 2023 05; 25(5):463-471. View Abstract

  41. The diagnosis of severe combined immunodeficiency: Implementation of the PIDTC 2022 Definitions. J Allergy Clin Immunol. 2023 02; 151(2):547-555.e5. View Abstract

  42. T-cell depleted haploidentical hematopoietic cell transplantation for pediatric malignancy. Front Pediatr. 2022; 10:987220. View Abstract

  43. Durable Engraftment and Excellent Overall Survival After CD34-Selected Peripheral Blood Stem Cell Boost in Pediatric Patients With Poor Graft Function Following Allogeneic Stem Cell Transplantation. Transplant Cell Ther. 2023 01; 29(1):46.e1-46.e6. View Abstract

  44. Dominant epitopes presented by prevalent HLA alleles permit wide use of banked CMVpp65 T cells in adoptive therapy. Blood Adv. 2022 08 23; 6(16):4859-4872. View Abstract

  45. Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC. Blood. 2022 08 18; 140(7):685-705. View Abstract

  46. Viral infection in hematopoietic stem cell transplantation: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review on the role of cellular therapy in prevention and treatment. Cytotherapy. 2022 09; 24(9):884-891. View Abstract

  47. Early intestinal microbial features are associated with CD4 T-cell recovery after allogeneic hematopoietic transplant. Blood. 2022 05 05; 139(18):2758-2769. View Abstract

  48. Acute myeloid leukemia with an MN1-ETV6 fusion in a young child with Down syndrome. Cold Spring Harb Mol Case Stud. 2022 04; 8(3). View Abstract

  49. An ISCT Stem Cell Engineering Committee Position Statement on Immune Reconstitution: the importance of predictable and modifiable milestones of immune reconstitution to transplant outcomes. Cytotherapy. 2022 04; 24(4):385-392. View Abstract

  50. Towards a standard of care in transplant for WAS. Blood. 2022 03 31; 139(13):1935-1936. View Abstract

  51. Successful treatment and integrated genomic analysis of an infant with FIP1L1-RARA fusion-associated myeloid neoplasm. Blood Adv. 2022 02 22; 6(4):1137-1142. View Abstract

  52. Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantation. Blood Adv. 2022 02 08; 6(3):1054-1063. View Abstract

  53. Time to initiation of pre-emptive therapy for cytomegalovirus impacts overall survival in pediatric hematopoietic stem cell transplant recipients. Cytotherapy. 2022 04; 24(4):428-436. View Abstract

  54. Lentiviral globin gene therapy with reduced-intensity conditioning in adults with ß-thalassemia: a phase 1 trial. Nat Med. 2022 01; 28(1):63-70. View Abstract

  55. Curative therapy for hemoglobinopathies: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review comparing outcomes, accessibility and cost of ex vivo stem cell gene therapy versus allogeneic hematopoietic stem cell transplantation. Cytotherapy. 2022 03; 24(3):249-261. View Abstract

  56. Real-Time Reflectance Confocal Microscopy of Cutaneous Graft-versus-Host Disease Correlates with Histopathology. Transplant Cell Ther. 2022 01; 28(1):51.e1-51.e14. View Abstract

  57. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2021 08; 27(8):642-649. View Abstract

  58. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders: beyond chemotherapy treatment. Cancer Drug Resist. 2021; 4:646-664. View Abstract

  59. Donor-Host Lineage-Specific Chimerism Monitoring and Analysis in Pediatric Patients Following Allogeneic Stem Cell Transplantation: Influence of Pretransplantation Variables and Correlation with Post-Transplantation Outcomes. Transplant Cell Ther. 2021 09; 27(9):780.e1-780.e14. View Abstract

  60. CD4+ T-cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: a dual-center validation. Blood. 2021 02 11; 137(6):848-855. View Abstract

  61. Correction to: Infections in Infants with SCID: Isolation, Infection Screening and Prophylaxis in PIDTC Centers. J Clin Immunol. 2021 Feb; 41(2):498-500. View Abstract

  62. Adoptive therapy with CMV-specific cytotoxic T lymphocytes depends on baseline CD4+ immunity to mediate durable responses. Blood Adv. 2021 01 26; 5(2):496-503. View Abstract

  63. Expanding the toolbox to combat a pandemic. Blood. 2020 12 17; 136(25):2847-2848. View Abstract

  64. Infections in Infants with SCID: Isolation, Infection Screening, and Prophylaxis in PIDTC Centers. J Clin Immunol. 2021 01; 41(1):38-50. View Abstract

  65. Adenovirus Viral Kinetics and Mortality in Ex Vivo T Cell-Depleted Hematopoietic Cell Transplant Recipients With Adenovirus Infection From a Single Center. J Infect Dis. 2020 09 01; 222(7):1180-1187. View Abstract

  66. Rapid Virologic Response to Brincidofovir in Children with Disseminated Adenovirus Infection. Infect Chemother. 2021 Sep; 53(3):572-577. View Abstract

  67. Early CD4+ T cell reconstitution as predictor of outcomes after allogeneic hematopoietic cell transplantation. Cytotherapy. 2020 09; 22(9):503-510. View Abstract

  68. Reticular dysgenesis caused by an intronic pathogenic variant in AK2. Cold Spring Harb Mol Case Stud. 2020 06; 6(3). View Abstract

  69. Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report. Blood. 2020 06 04; 135(23):2094-2105. View Abstract

  70. Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant. Bone Marrow Transplant. 2020 11; 55(11):2160-2169. View Abstract

  71. Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey. Front Immunol. 2020; 11:239. View Abstract

  72. Study 275: Updated Expanded Access Program for Remestemcel-L in Steroid-Refractory Acute Graft-versus-Host Disease in Children. Biol Blood Marrow Transplant. 2020 05; 26(5):855-864. View Abstract

  73. Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. J Clin Invest. 2020 02 03; 130(2):733-747. View Abstract

  74. A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2020 05; 26(5):845-854. View Abstract

  75. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood. 2019 12 26; 134(26):2361-2368. View Abstract

  76. Therapeutic advantages provided by banked virus-specific T-cells of defined HLA-restriction. Bone Marrow Transplant. 2019 08; 54(Suppl 2):759-764. View Abstract

  77. Establishing a standardized system for review and adjudication of chronic graft-vs-host disease data in accordance with the National Institutes Consensus criteria. Adv Cell Gene Ther. 2019 Oct; 2(4). View Abstract

  78. The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018). J Allergy Clin Immunol. 2019 01; 143(1):405-407. View Abstract

  79. SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. Blood. 2018 10 25; 132(17):1737-1749. View Abstract

  80. Two-year-old female with EBV-positive diffuse large B-cell lymphoma and subsequent CNS involvement with neurolymphomatosis. Pediatr Blood Cancer. 2018 12; 65(12):e27415. View Abstract

  81. B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation. Blood. 2018 06 28; 131(26):2967-2977. View Abstract

  82. Allogeneic Matched Related Donor Bone Marrow Transplantation for Pediatric Patients With Severe Aplastic Anemia Using "Low-dose" Cyclophosphamide, ATG Plus Fludarabine. J Pediatr Hematol Oncol. 2018 05; 40(4):e220-e224. View Abstract

  83. Reprint of: Virus-Specific T Cells: Broadening Applicability. Biol Blood Marrow Transplant. 2018 03; 24(3S):S1-S6. View Abstract

  84. Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience. Leuk Lymphoma. 2018 08; 59(8):1861-1870. View Abstract

  85. Virus-Specific T Cells: Broadening Applicability. Biol Blood Marrow Transplant. 2018 01; 24(1):13-18. View Abstract

  86. Corrigendum: Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56bright NKG2A+++ Cells, and Yet Display Increased Degranulation and Higher Perforin Content. Front Immunol. 2017; 8:1244. View Abstract

  87. Epstein-Barr virus lymphoproliferative disease after solid organ transplantation. Cytotherapy. 2017 11; 19(11):1270-1283. View Abstract

  88. Approach to adenovirus infections in the setting of hematopoietic cell transplantation. Curr Opin Infect Dis. 2017 Aug; 30(4):377-387. View Abstract

  89. Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56bright NKG2A+++ Cells, and Yet Display Increased Degranulation and Higher Perforin Content. Front Immunol. 2017; 8:798. View Abstract

  90. Is My Child Safe? Biol Blood Marrow Transplant. 2017 09; 23(9):1415-1416. View Abstract

  91. A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies. Biol Blood Marrow Transplant. 2017 Dec; 23(12):2088-2095. View Abstract

  92. Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study. Blood. 2017 04 20; 129(16):2308-2315. View Abstract

  93. Ex Vivo CD34+-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response. Biol Blood Marrow Transplant. 2017 Mar; 23(3):452-458. View Abstract

  94. Allogeneic hematopoietic stem cell transplantation for nonmalignant hematologic disorders using chemotherapy-only cytoreductive regimens and T-cell-depleted grafts from human leukocyte antigen-matched or -mismatched donors. Pediatr Hematol Oncol. 2016 Sep; 33(6):347-358. View Abstract

  95. Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa. Biol Blood Marrow Transplant. 2016 08; 22(8):1449-1454. View Abstract

  96. Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections. Bone Marrow Transplant. 2016 Sep; 51(9):1163-72. View Abstract

  97. Late effects in patients with Fanconi anemia following allogeneic hematopoietic stem cell transplantation from alternative donors. Bone Marrow Transplant. 2016 Jul; 51(7):938-44. View Abstract

  98. Histopathologic Features of Cutaneous Acute Graft-Versus-Host Disease in T-Cell-Depleted Peripheral Blood Stem Cell Transplant Recipients. Am J Dermatopathol. 2015 Jul; 37(7):523-9. View Abstract

  99. T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells. Bone Marrow Transplant. 2015 Jun; 50 Suppl 2:S43-50. View Abstract

  100. Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia. Biol Blood Marrow Transplant. 2015 Sep; 21(9):1663-78. View Abstract

  101. Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation. Biol Blood Marrow Transplant. 2015 May; 21(5):920-5. View Abstract

  102. Treatment of cytomegalovirus retinitis with cytomegalovirus-specific T-lymphocyte infusion. Ophthalmic Surg Lasers Imaging Retina. 2015 Jan; 46(1):80-2. View Abstract

  103. Are clinical trials with mesenchymal stem/progenitor cells too far ahead of the science? Lessons from experimental hematology. Stem Cells. 2014 Dec; 32(12):3055-61. View Abstract

  104. High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. Blood. 2015 Jan 01; 125(1):199-205. View Abstract

  105. High-dose cyclophosphamide for the treatment of refractory T-cell acute lymphoblastic leukemia in children. J Pediatr Hematol Oncol. 2014 Jul; 36(5):e265-70. View Abstract

  106. Safe mobilization of CD34+ cells in adults with ß-thalassemia and validation of effective globin gene transfer for clinical investigation. Blood. 2014 Mar 06; 123(10):1483-6. View Abstract

  107. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. Biol Blood Marrow Transplant. 2014 Feb; 20(2):229-35. View Abstract

  108. Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation. Pediatr Blood Cancer. 2013 Dec; 60(12):2018-24. View Abstract

  109. Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match. Biol Blood Marrow Transplant. 2013 Jun; 19(6):904-11. View Abstract

  110. Posttransplant lymphoproliferative disorder complicating hematopoietic stem cell transplantation in a patient with dyskeratosis congenita. Int J Surg Pathol. 2013 Oct; 21(5):520-5. View Abstract

  111. T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease. Biol Blood Marrow Transplant. 2013 Feb; 19(2):208-13. View Abstract

  112. Paroxysmal nocturnal hemoglobinuria in pediatric patients. Pediatr Blood Cancer. 2012 Sep; 59(3):525-9. View Abstract

  113. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood. 2012 Mar 15; 119(11):2644-56. View Abstract

  114. Thrombolytic therapy is effective in paroxysmal nocturnal hemoglobinuria: a series of nine patients and a review of the literature. Haematologica. 2012 Mar; 97(3):344-52. View Abstract

  115. Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia. Biol Blood Marrow Transplant. 2012 Mar; 18(3):473-80. View Abstract

  116. Novel strategies for adoptive therapy following HLA disparate transplants. Best Pract Res Clin Haematol. 2011 Sep; 24(3):381-91. View Abstract

  117. Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Jan; 18(1):145-9. View Abstract

  118. T-cell-depleted hematopoietic SCT from unrelated donors for the treatment of congenital amegakaryocytic thrombocytopenia. Bone Marrow Transplant. 2012 May; 47(5):744-6. View Abstract

  119. Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT). Biol Blood Marrow Transplant. 2011 Nov; 17(11):1708-13. View Abstract

  120. Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011 Sep; 17(9):1316-26. View Abstract

  121. Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood. 2010 Dec 02; 116(23):5045-9. View Abstract

  122. Strategy for a multicenter phase I clinical trial to evaluate globin gene transfer in beta-thalassemia. Ann N Y Acad Sci. 2010 Aug; 1202:52-8. View Abstract

  123. Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia. Br J Haematol. 2008 Mar; 140(6):644-55. View Abstract

  124. Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure. Biol Blood Marrow Transplant. 2007 Nov; 13(11):1313-23. View Abstract

  125. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies. Biol Blood Marrow Transplant. 2007 Feb; 13(2):235-44. View Abstract

  126. Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants. Blood. 2006 Oct 01; 108(7):2470-5. View Abstract

  127. Regulation of thymus size by competition for stromal niches among early T cell progenitors. J Immunol. 2004 Aug 01; 173(3):1604-11. View Abstract

  128. Functional assessment of alphaEbeta7/E-cadherin interactions in the steady state postnatal thymus. Clin Dev Immunol. 2004 Jun; 11(2):135-41. View Abstract

  129. Critical role for CXCR4 signaling in progenitor localization and T cell differentiation in the postnatal thymus. J Immunol. 2003 Nov 01; 171(9):4521-7. View Abstract

  130. Stromal cells provide the matrix for migration of early lymphoid progenitors through the thymic cortex. J Immunol. 2002 Oct 15; 169(8):4354-61. View Abstract

  131. Mapping precursor movement through the postnatal thymus reveals specific microenvironments supporting defined stages of early lymphoid development. J Exp Med. 2001 Jul 16; 194(2):127-34. View Abstract

  132. Cell migration and the anatomic control of thymocyte precursor differentiation. Semin Immunol. 2000 Oct; 12(5):435-44. View Abstract

  133. A novel fluorescence-based system for assaying and separating live cells according to VDJ recombinase activity. Mol Cell Biol. 1990 Apr; 10(4):1697-704. View Abstract
BESbswy